この記事は最初に2025年10月2日に英語で公開されました スプルーソン＆ファーガソンによる、過去1年間におけるオーストラリアの医薬品特許法に関する主要な動向の評論へようこそ。
この記事は最初に2025年10月2日に英語で公開されました スプルーソン＆ファーガソンによる、過去1年間におけるオーストラリアの医薬品特許法に関する主要な動向の評論へようこそ。
Welcome to Spruson & Ferguson’s review of the most notable developments in Australian pharmaceutical patent law in the past year.The year has seen a series of landmark decisions from...
Welcome to Spruson & Ferguson’s review of the most notable developments in Australian pharmaceutical patent law in the past...
After several years of litigation, the fate of two patents owned by Bayer Intellectual Property GmbH (Bayer) covering dosages and uses of rivaroxaban has culminated in revocation and a...
After several years of litigation, the fate of two patents owned by Bayer Intellectual Property GmbH (Bayer) covering dosages...
A recent Full Federal Court decision in Australia provides a useful insight as to how a Court in Australia will calculate damages in proceedings concerning the infringement of a...
A recent Full Federal Court decision in Australia provides a useful insight as to how a Court in Australia...